Peptides for Joints and Tendons

Peptides for Joints and Tendons: Where the Healing Claims Come From

BPC-157, TB-500 and the rest of the healing group. What the animal evidence shows, what the human evidence does not, and why this is the category with the widest gap.

Caroline S · Published 2026-09-07

Illustration

The category with the widest gap

Every category in this library has a gap between animal and human evidence. This one has the widest — and, unusually, that is because the animal evidence is unusually good.

Why the animal work is so strong

Tendon and muscle injury is easy to model well. A standardised injury can be created, treated and measured objectively: tensile strength, healing time, tissue structure under a microscope. There is little room for interpretation.

That produces clean, repeatable results, and for BPC-157 in particular it has produced a large and internally consistent literature spanning skin, muscle, bone, ligament and tendon, from more than one research group.

None of it is in people.

What that means for reading claims

When the animal evidence is weak, a confident claim is obviously overreaching. When it is strong — as here — the overreach is much harder to spot, because the citations are real, numerous and consistent.

The sentence to watch for is the one that moves from "in rats" to "helps you recover" without marking the transition. In this category that sentence is almost always present, and it is almost always unmarked.

The compounds

BPC-157 — fifteen amino acids, from a fragment of a protein in gastric juice. The largest animal literature in this category and a thin human record. Notably, it is not currently on the FDA's Category 2 compounding list, contrary to what most pages still say; it appears there among withdrawn nominations.

TB-500 — and this one carries a citation problem. TB-500 is Ac-LKKTETQ, seven amino acids corresponding to residues 17-23 of the 43-amino-acid protein thymosin beta-4. The two names are used interchangeably almost everywhere. They are not the same molecule, and a study of the full protein is not a study of the fragment.

Pentadeca arginate — marketed as a more stable alternative to BPC-157, and appearing largely after regulatory attention turned toward BPC-157. Its own evidence base is thinner than the compound it is sold as an upgrade to.

Growth hormone secretagogues are sometimes included on the reasoning that growth hormone and IGF-1 are involved in tissue repair. That is true as biology and is a long way from evidence that pushing the hormone heals an injury faster.

What each entry says

The best known of them — the flagship, and its current regulatory status
TB-500 — why it is not thymosin beta-4
The 43-residue parent protein itself — a real clinical programme, none of it about tendons
What are peptides — the starting point

Last checked

2026-09-07.

Frequently asked questions

Which peptides are used for joint and tendon healing?

BPC-157 and TB-500 dominate, with pentadeca arginate appearing more recently as a marketed alternative to BPC-157. The growth hormone secretagogues are sometimes included on the reasoning that growth hormone and IGF-1 are involved in tissue repair.

Is there human evidence that any of them heal tendons?

Not to a standard worth relying on. BPC-157's published human record is very limited despite a large animal literature. TB-500's published record under that name is weighted toward analytical chemistry — methods for detecting it in samples — rather than clinical outcomes. No peptide is an approved treatment for tendon, ligament or joint injury.

Why is the animal evidence so much stronger here than in other categories?

Because tendon and muscle injury is unusually easy to model in animals. You can create a standardised injury, treat it, and measure recovery objectively — tensile strength, healing time, tissue structure. That produces clean, repeatable results. It also means the gap between animal and human evidence is wider here than almost anywhere else in this library: the animal work is genuinely good, which makes the absence of human work more conspicuous rather than less.

Is TB-500 the same as thymosin beta-4?

No, and it matters for reading citations. TB-500 is Ac-LKKTETQ, a seven-amino-acid fragment corresponding to residues 17 to 23 of the 43-amino-acid protein thymosin beta-4. A study on the full protein is not automatically a study on TB-500, and once the two names are treated as interchangeable that substitution becomes invisible.

What about pentadeca arginate?

It is marketed as a more stable alternative to BPC-157, and appeared largely after regulatory attention turned toward BPC-157. Its own published evidence base is thinner than BPC-157's, which is worth knowing given it is often presented as an upgrade.